Alpha-MSH-derived tripeptide
KPV
A three-amino-acid research peptide whose small size does not remove identity, purity, formulation, or safety questions.
Why it is discussed
Inflammation, skin, gut, and wound-healing claims
KPV is discussed as a small alpha-MSH-derived peptide in inflammation, skin, gastrointestinal, and wound-healing conversations. FDA reports that it has not identified human exposure data, so proposed benefits remain unestablished for human use.
What it is
A three-amino-acid fragment studied in inflammation models.
KPV stands for lysine-proline-valine. This tripeptide corresponds to the final three amino acids of alpha-melanocyte-stimulating hormone, or alpha-MSH. A fragment is not automatically equivalent to the complete hormone and need not reproduce all its receptor effects.
How it works
Experimental effects on cellular inflammatory signals.
In intestinal epithelial and immune-cell experiments, the peptide transporter PepT1 helped move KPV into cells. The researchers reported reduced activity in NF-kappa B and MAP kinase signaling, pathways that help control inflammatory responses, along with reduced production of inflammatory signaling molecules.
The same research examined chemically induced colitis in mice and reported reduced inflammation. Those findings support a research hypothesis; they do not establish a treatment mechanism or clinical benefit for human inflammatory bowel disease.
Transport into a particular cell model does not establish absorption or tissue exposure from an oral, topical, or injectable preparation. KPV should not be presented as a proven general anti-inflammatory therapy.
Scientific / evidence sources
Evidence at a glance
What is established—and what is not.
Preclinical evidence without established human exposure
Preclinical studies support research interest in inflammatory, skin, gastrointestinal, and wound pathways.
FDA reports no identified human exposure data, leaving human effectiveness, exposure, and safety unestablished.
Regulatory status
Canada and the United States are checked separately.
Health Canada lists injectable KPV among unauthorized peptide drugs and states that unauthorized drugs have not been assessed for safety, efficacy, or quality.
No FDA-approved product. FDA states it has not identified human exposure data and lacks information needed to assess harm.
Regulatory status describes product authorization and relevant regulatory context. It is not a complete legal opinion about possession, importation, prescribing, sale, or professional practice.
If you are reviewing a product report
The molecule profile and the testing report answer different questions.
This page summarizes evidence and regulatory context. A laboratory report may address identity, purity, or quantity for one submitted sample; it does not transfer clinical evidence or product authorization.